SCHEMBL27201601

SCHEMBL27201601

CN(C)CCNC(=O)c1csc2ccc(-c3ccc4ccnc(N)c4c3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 2/20 0.47
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
JAK3 P52333 1/20 0.42
CHEK1 O14757 4/20 0.42
MAP4K4 O95819 2/20 0.42
WNT1 P04628 1/20 0.40
DYRK1A Q13627 1/20 0.40
KLKB1 P03952 1/20 0.40
PRKD3 O94806 1/20 0.40
PRKD1 Q15139 1/20 0.40
PRKD2 Q9BZL6 1/20 0.40
RAD52 P43351 2/20 0.39
AKT3 Q9Y243 1/20 0.39
BRAF P15056 1/20 0.39
MOK Q9UQ07 1/20 0.38
ALOX5AP P20292 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30834169 1.00 CHEK2 (0.47) CHEK2JAK2JAK1TYK2JAK3
SCHEMBL27201334 0.79 CHEK2 (0.50) CHEK2JAK2JAK1TYK2JAK3
SCHEMBL27201439 0.78 PRKD3 (0.45) CHEK2JAK2JAK1TYK2JAK3
SCHEMBL30885290 0.78 PRKD3 (0.45) CHEK2JAK2JAK1TYK2JAK3
SCHEMBL27201405 0.78 DYRK1A (0.67) WNT1DYRK1A
SCHEMBL30834184 0.77 CHUK (0.46) WNT1DYRK1AKLKB1PRKD3PRKD1
SCHEMBL27201391 0.77 CHUK (0.46) WNT1DYRK1AKLKB1PRKD3PRKD1
SCHEMBL27201529 0.76 MAP4K4 (0.43) CHEK2JAK2JAK1TYK2JAK3
SCHEMBL30885239 0.74 CHUK (0.56) MAP4K4WNT1DYRK1APRKD3PRKD1
SCHEMBL27201568 0.74 CHUK (0.56) MAP4K4WNT1DYRK1APRKD3PRKD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US claimed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO claimed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP CHEK2 548/4885JAK2 1493/4885JAK1 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.